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Major depressive disorder (MDD) is a severe psychiatric syndrome with very high 
socioeconomic impact worldwide (Global Burden of Disease Study 2013 Collaborators, 
2015). This is attributable to three main factors: i) MDD is a highly prevalent disorder in 
the general population, ii) depressive episodes have long duration and occur during 
active periods of adult life, resulting in very large labor costs, and iii) standard MDD 
treatments have limited efficacy, leaving a high percentage of patients with incomplete 
responses and poor quality of life, thus increasing suicide risk (Rush et al., 2006). 
Based on clinical and preclinical studies, MDD may be associated with altered 
structural and synaptic plasticity, stress- or immune-related pathology and genetic 
polymorphisms in brain circuits regulating mood and cognition (Ota and Duman, 2013). 
In this context, RNA interference (RNAi) may be a useful tool to examine the role of 
candidate genes in the pathophysiology and treatment of MDD. Hence, RNAi can be 
used as a therapeutic tool to silence targets involved in the disease process. However, 
despite its enormous potential, in vivo use of RNAi is limited due to the difficulty to 
deliver sequences of small RNAs (small interfering RNA-siRNA) to the desired 
neurons/circuits in mammalian brain. Our strategy has been to develop conjugate 
siRNA molecules (C-siRNA) in which the siRNA sequence was covalently bound to a 
selective serotonin reuptake inhibitor (SSRI-sertraline) in order to selectively 
accumulate it by the dense network of serotonin axon terminals in brain. The amounts 
(typically 0.5-2 nmol/day) of C-siRNA directed against 5-HT1A receptors (5-HT1A-R) or 
the serotonin transporter (SERT) were then administered intranasally to mice and C-
siRNA sequences were localized into raphe serotonin neurons (Bortolozzi et al., 2012; 
Ferrés-Coy et al., 2016). Using this strategy, we discerned the role of pre- and 
postsynaptic 5-HT1A-R in the response to stress, the anxiety phenotype and the 
response to antidepressant treatments. Interestingly, the selective silencing of 
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presynaptic 5-HT1A autoreceptors was sufficient to elicit antidepressant-like effects in 
mice thanks to the increased capability of serotonergic neurons to release serotonin 
during stressful situations (Bortolozzi et al., 2012; Ferrés-coy et al., 2013).  
Likewise, we employed this approach to silence SERT expression/function. 
Intranasal administration of a C-siRNA targeting SERT (C-SERT-siRNA) evoked rapid 
and robust antidepressant-like responses in mice, including elevated forebrain 
serotonin levels, presynaptic 5-HT1A-R desensitization, increased hippocampal 
neurogenesis and expression of trophic factors, and increased dendritic complexity. 
Further, C-SERT-siRNA reversed depressive-like behaviors in a mouse model of 
depression. C-SERT-siRNA evoked all these responses in 1 week whereas SSRI 
fluoxetine required 1 month (Ferrés-Coy et al., 2016). In addition, we are using this 
strategy to knockdown other genes potentially involved in stress resilience (e.g., TASK-
3 channels; Ferrés-Coy et al., unpublished observations) and to target catecholamine 
neurons, by linking siRNA or antisense oligonucleotide sequences to the respective 
transporter inhibitors.  
Despite the many advantages of siRNA to treat brain diseases, many 
challenges remain, including off-target effects, rapid degradation, immune response 
and, poor cellular uptake and selectivity as well as in vivo delivery. Rational design 
strategies, predictive models based on second-generation algorithms, antibody and 
chemical modifications and nanocarriers offer significant opportunities to overcome 
some of the above problems. Although it is still soon to know the impact of RNAi-based 
therapies on MDD treatment, our approach to deliver C-siRNA sequences to serotonin 
neurons through the intranasal route has proven successful in order to elicit rapid and 
robust antidepressant-like actions in rodents, showing a high potential translational 
value.  
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